COT Cotinga Pharmaceuticals Inc

Critical Outcome Technologies Inc. ("COTI" or the "Company") (TSX VENTURE:COT),
the bioinformatics and accelerated drug discovery company, announced today it
has submitted an Orphan Drug Application to the U.S. Food and Drug
Administration (FDA) for its lead cancer drug candidate, COTI-2, for the
treatment of ovarian cancer.


"We believe that COTI-2, with its p53 dependent mechanism of action, represents
a significant therapeutic advantage over treatments currently available for
ovarian and other gynecological cancers," said Dr. Wayne Danter, President and
CEO. "The fact that more than 95% of ovarian cancers have a p53 gene mutation,
combined with the extent of the unmet medical need in ovarian cancer patients,
makes a treatment for this indication one of our top priorities. If COTI-2 is
granted Orphan Drug status, the financial benefits in the future could be
substantial and COTI-2 would be directed down a unique development pathway
within the FDA, including the possibility of an expedited regulatory process and
the potential for fewer patients to be required in clinical trials."


The Orphan Drug Designation may qualify the Company for several benefits under
the U.S. Orphan Drug Act of 1983 (ODA), as amended. These benefits may include a
seven-year period of orphan drug exclusivity upon product approval, fee
reductions, assistance in study design from the FDA, potential for expedited
drug development and eligibility for drug grants.


About Orphan Drug Designation

Under the Orphan Drug Act, the FDA may grant the Orphan Drug Designation to
facilitate drug development for drugs that target conditions affecting fewer
than 200,000 patients in the United States each year, while providing a
significant therapeutic advantage over existing therapies. The first new drug
application to receive FDA approval for a particular active ingredient to treat
a particular disease with FDA orphan drug designation is entitled to a
seven-year exclusive marketing period in the U.S. for that product, for that
indication.


About Critical Outcome Technologies Inc.

COTI is a leading-edge technology company specializing in accelerating the
discovery and development of small molecules - dramatically reducing the time
and cost to bring new drugs to market. COTI's proprietary artificial
intelligence system, CHEMSAS(R), utilizes a series of predictive computer models
to identify compounds with a high probability of being successfully developed
from disease specific drug discovery through chemical optimization and
preclinical testing. These compounds are targeted for a variety of diseases,
particularly those for which current treatments are either lacking or
ineffective.


For more information, visit www.criticaloutcome.com.

Follow @CriticalOutcome on Twitter at http://twitter.com/CriticalOutcome.

Notice to Readers

Information contained in this press release may contain certain statements,
which constitute "forward- looking statements" within the meaning of the
Securities Act (Ontario) and applicable securities laws. For example, the
statement "... the financial benefits in the future could be substantial and
COTI-2 would be directed down a unique development pathway within the FDA,
including the possibility of an expedited regulatory process and the potential
for fewer patients to be required in clinical trials" and "... may qualify the
Company for several benefits under the U.S. Orphan Drug Act of 1983 (ODA), as
amended. These benefits may include a seven-year period of orphan drug
exclusivity upon product approval, fee reductions, assistance in study design
from the FDA, potential for expedited drug development and eligibility for drug
grants" are forward-looking statements. Forward-looking statements by their
nature are not guarantees of future performance and are based upon management's
current expectations, estimates, projections and assumptions. COTI operates in a
highly competitive environment that involves significant risks and
uncertainties, which could cause actual results to differ materially from those
anticipated in these forward-looking statements. Management of COTI considers
the assumptions on which these forward-looking statements are based to be
reasonable, but as a result of the many risk factors, cautions the reader that
actual results could differ materially from those expressed or implied in these
forward-looking statements. Information in this press release should be
considered accurate only as of the date of the release and may be superseded by
more recent information disclosed in later press releases, filings with the
securities regulatory authorities or otherwise.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Critical Outcome Technologies Inc.
Dr. Wayne Danter
President & CEO
519-858-5157
wdanter@criticaloutcome.com


Heisler Communications
Trevor Heisler
Investor Relations
416-500-8061
trevor@heislercommunications.com

Cotinga Pharmaceuticals (TSXV:COT)
Historical Stock Chart
From Dec 2024 to Jan 2025

Cotinga Pharmaceuticals (TSXV:COT)
Historical Stock Chart
From Jan 2024 to Jan 2025